展覽品 31.2

​

認證

​

我，Raul Parra，證明：

​

1. 我已審閱梅里特醫療系統公司（以下簡稱「註冊公司」）此季度報告10-Q（以下簡稱「報告」）

​

2. 根據我的知識，本報告不包含任何關鍵事實不實的陳述，也未遺漏必要的關鍵事實，以使在製作這些陳述的相關情況下，這些陳述對所涵蓋的期間不誤導；

​

3. 根據我的知識，財務報表及本報告中包含的其他財務信息，對報告期內註冊公司的財務狀況、經營成果和現金流量方面均以所有重大方面公平呈現；

​

4. 註冊者的其他認證官員和我負責建立和維護披露控件和程序（由《交易所法規》第13a-15(e)和15d-15(e)條定義）和內部財務報告控件（由《交易所法規》第13a-15(f)和15d-15(f)條定義）爲註冊者，並已：

​

a）設計了這樣的披露控件和程序，或者在我們的監督下導致這樣的披露控件和程序的設計，以確保與註冊者及其合併附屬公司相關的重要信息在本報告準備期間特別由這些實體內的其他人員告知我們；

​

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

​

c) evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

​

d) disclosed in this Report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

​

5.      The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

​

所有板塊中，設計或內部控制操作中可能對報告財務信息的記錄、處理、彙總和報告產生實質影響的顯著缺陷和實質性弱點；以及

​

包括但不限於涉及管理層或其他在登記公司財務報告內部控制中具有重要角色的員工的任何欺詐問題，不論其是否影響業務實質。

​

​